Axonics Modulation Tech (AXNX) Financial Analysis & Valuation | Quarter Chart
Axonics Modulation Tech (AXNX)
AXNXPrice: $70.98
Fair Value: 🔒
🔒score
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as feca... more
Axonics, Inc., a medical technology company, engages in the development and commercialization of sac... more
Description
Shares
| Market Cap | $3.63B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Raymond W. Cohen |
| IPO Date | 2018-10-31 | CAGR | — |
| Employees | 797 | Website | www.axonics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.43% | Total Yield | -0.43% |
AXNX chart loading...
Fundamentals
Technicals
| Enterprise Value | $3.35B | P/E Ratio | -709.8 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 9.9 | P/B Ratio | 5.46 |
| P/CF Ratio | -1728.08 | P/FCF Ratio | -651.77 |
| EPS | $-0.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 58.57% | Gross Margin | 0.75% |
| Operating Margin | -0.07% | Profit Margin | -0.02% |
| ROE | -0.01% | ROA | -0.01% |
| ROCE | -0.04% | Current Ratio | 10.73 |
| Quick Ratio | 8.98 | Cash Ratio | 2.29 |
| Debt/Equity | 0.04 | Interest Coverage | — |
| Altman Z Score | 20.38 | Piotroski Score | 4 |